Severe Sepsis
193
2
4
121
Key Insights
Highlights
Success Rate
83% trial completion
Published Results
20 trials with published results (10%)
Research Maturity
121 completed trials (63% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
12.4%
24 terminated out of 193 trials
83.4%
-3.1% vs benchmark
19%
37 trials in Phase 3/4
17%
20 of 121 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 121 completed trials
Clinical Trials (193)
Clinical Study on Monitoring the Plasma Concentration of Ceftazidime-Avibactam in Critically Ill Patients
Plasma Exchange in Children With Severe Sepsis and Septic Shock
Descriptive Study of the Evolution in Proportion of Regulatory B Lymphocytes in Patients Hospitalized in Intensive Care for Severe Sepsis
Zinc Therapy in Critical Illness
GM-CSF to Decrease ICU Acquired Infections
Monocyte Distribution Width (MDW) in the General Population of Emergency Department Patients With and Without Bacteremia
De-escalation of Empirical Antimicrobial Therapy Study in Severe Sepsis
A Multi-Center Data System and Collaborative Network in China for Severe Infection and Sepsis Children
L-carnitine as an Adjunct Treatment for Septic Shock Patients With Acute Kidney Injury
Alveolar Dead Space as Predictor of Organ Failure in Severe Sepsis
Endothelium in Severe Sepsis
Early Metabolic Resuscitation for Septic Shock
Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy - Observational Long-term Outcome Follow up
Sepsis Clinical Decision Support [CDS] Master Enrollment Study Protocol
Plasma Inducible Nitric Oxide Synthase (iNOS) Assay and Sepsis Study
The Efficacy of Si-Ni-Tang (a Chinese Herbal Formula) for Severe Sepsis
Symphony IL-6 Study in Patients at Risk of Severe Sepsis
Septic cArdiac Deficiency and MenIngococcal seveRe Sepsis
Symphony IL-6 Cutoff Establishment Study for Patients at Risk of Severe Sepsis Due to COVID-19
Symphony IL-6 Cutoff Validation Study for Patients at Risk of Severe Sepsis